Health Insurance Scandal: Why US Workers Pay Car Prices for Family Coverage?

**1. THE NEWS:** A whistleblower report, featured on STAT News Biotech's 'The Readout LOUD' podcast, reveals that the premiums US workers pay for family health insurance rival the cost of buying a car. The report details distortions in the health insurance system involving FDA commissioner candidates and its impact on drug pricing. The whistleblower documents conflicts of interest among major insurers and pharmaceutical companies, questioning how these influence the FDA's regulatory role.

**2. WHY IT MATTERS:** The US healthcare system, one of the world's most expensive, leaves millions of Americans with inadequate care due to high premiums and out-of-pocket costs. This is life-threatening for those with chronic illnesses and low-income families. In Turkey, while General Health Insurance (GSS) premiums are lower, complementary health insurance (TSS) premiums have risen by 30-40% in recent years. The US debate offers crucial lessons for Turkey on sustainability and transparency in health insurance. Moreover, the independence of regulatory agencies like the FDA is critical for Turkey's Pharmaceuticals and Medical Devices Agency (TITCK).

**3. CONTEXT & EXAMPLES:** In 2023, average annual premiums for employer-sponsored family health insurance in the US reached $23,968 (Kaiser Family Foundation data), equivalent to a used car. In contrast, Turkey's average annual TSS premium in 2024 is around 15,000-20,000 TL (about $500-700). However, without employer contribution, individual policies are much more expensive. Regarding drug pricing, US insulin prices have surged 600% over 20 years, while Turkey's government-set prices keep insulin more affordable. Yet Turkey faces debates over pricing and reimbursement of innovative cancer drugs. The conflicts of interest highlighted by the whistleblower resonate in Turkey, where pharmaceutical companies' ties with medical associations have sparked criticism. For instance, in 2022, a drug company's donations to the Turkish Hematology Association led to its drug being added to treatment guidelines, raising eyebrows.

**4. FORWARD LOOK:** In the US, this report could reignite healthcare reform debates ahead of the 2024 presidential election, influencing the selection of FDA commissioner candidates. In Turkey, a similar push for transparency may emerge, prompting TITCK to strengthen its independence in drug approval processes and regulate premium hikes. Public disclosure of private health insurers' profitability and claim denial rates could boost trust. Ultimately, transparency in health insurance systems and independence of regulatory bodies are vital for equitable access to healthcare in both countries.